Federated Hermes
ANTX icon

Federated Hermes’s AN2 Therapeutics ANTX Stock Holding History

Federated Hermes’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17K Sell
449
-7,873
-95% -$33.9K ﹤0.01% 1989
2026
Q1 		$28.5K Sell
8,322
-3,157
-28% -$6.51K ﹤0.01% 1743
2025
Q4 		$13.1K Sell
11,479
-403
-3% -$471 ﹤0.01% 1813
2025
Q3 		$15.1K Sell
11,882
-355
-3% -$406 ﹤0.01% 1837
2025
Q2 		$13K Hold
12,237
– – ﹤0.01% 1777
2025
Q1 		$16.6K Buy
12,237
+4,745
+63% +$5.97K ﹤0.01% 1754
2024
Q4 		$10.3K Buy
7,492
+4,486
+149% +$5.44K ﹤0.01% 1837
2024
Q3 		$3.22K Buy
3,006
+2,089
+228% +$3.63K ﹤0.01% 1901
2024
Q2 		$1.97K Buy
917
+706
+335% +$1.68K ﹤0.01% 1901
2024
Q1 		$686 Sell
211
-47
-18% -$511 ﹤0.01% 1976
2023
Q4 		$5.29K Buy
258
+160
+163% +$2.68K ﹤0.01% 1847
2023
Q3 		$1.58K Buy
+98
New +$1.11K ﹤0.01% 1986

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Federated Hermes's ANTX Position: Q2 2026 in Review

Federated Hermes reduced its AN2 Therapeutics (ANTX) stake by 95% in Q2 2026, selling an estimated $33.9K and leaving 449 shares worth $2.17K. The position accounts for ﹤0.01% of the portfolio, ranked #1989.

Federated Hermes first reported a position in ANTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $28.5K in Q1 2026. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Federated Hermes held 449 shares of AN2 Therapeutics worth $2.17K as of Q2 2026.
  • Federated Hermes sold 7,873 AN2 Therapeutics shares in Q2 2026, an estimated $33.9K.
  • AN2 Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1989 holding.
  • Federated Hermes first reported a position in AN2 Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Federated Hermes's AN2 Therapeutics position peaked at $28.5K in Q1 2026.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.